Table 2 Association between miR-148b-3p expression and clinicopathological parameters in 59 GIST patients
From: miR-148b-3p functions as a tumor suppressor in GISTs by directly targeting KIT
Characteristics | Number | Percent | Median exprssion of miR-148b-3p/U6 | P value |
|---|---|---|---|---|
Age (years) | ||||
  ≤ 55 | 37 | 62.71 | 1.49 ± 0.79 | 0.54 |
  > 55 | 22 | 37.29 | 1.36 ± 0.72 | |
Gender | ||||
 Male | 32 | 54.24 | 1.35 ± 0.79 | 0.33 |
 Female | 27 | 45.76 | 1.55 ± 0.73 | |
Primer sites | ||||
 Stomach | 21 | 35.59 | 1.59 ± 0.69 | 0.38 |
 Small instine | 22 | 37.29 | 1.28 ± 0.68 | |
 Others | 16 | 27.12 | 1.36 ± 0.82 |  |
Tumor size (cm) | ||||
  ≤ 5 | 30 | 50.85 | 1.74 ± 0.63 | 0.07 |
  > 5 to ≤10 | 19 | 32.20 | 1.19 ± 0.81 | |
  > 10 | 10 | 16.95 | 1.03 ± 0.77 | |
Histological type | ||||
 Spindle phenotype | 54 | 91.53 | 1.46 ± 0.76 | 0.85 |
 Epithelioid phenotype | 2 | 3.39 | 1.38 ± 0.91 | |
 Mixed phenotype | 3 | 5.08 | 1.20 ± 1.13 | |
Mitotic rate (per 50 HPFs) | ||||
  ≤ 5 | 32 | 54.24 | 1.91 ± 0.61 | < 0.001 |
 6 to 10 | 20 | 33.90 | 0.85 ± 0.45 | |
  > 10 | 7 | 11.86 | 0.98 ± 0.74 | |
National Institutes of Health risk group | ||||
 Very low to low risk | 21 | 35.60 | 2.11 ± 0.30 | < 0.001 |
 Intermediate risk | 19 | 32.20 | 1.26 ± 0.71 | |
 High risk | 19 | 32.20 | 0.88 ± 0.64 | |
Relapse | ||||
 Yes | 10 | 18.64 | 0.80 ± 0.41 | 0.04 |
 No | 49 | 81.36 | 1.58 ± 0.77 | |